Lydall Company Overview, Contact Details & Competitors

Q: What is Lydall's official website and social media links?

Lydall's official website is lydall.com. Lydall has social profiles on LinkedIn.

Q: How many employees does Lydall have currently?

Lydall has approximately 539 employees.

Q: What technology does Lydall use?

Lydall's tech stack includes Cognex, C++, Skype for Business, Pure Storage, Apple iCloud Mail.

Q: What is Lydall's NAICS code?

Lydall's NAICS code is 3332 (Industrial Machinery Manufacturing).

Insights

Gathering insights about Lydall…

Similar companies to Lydall

Lydall Tech Stack

Lydall uses 8 technology products and services including Microsoft SharePoint, Oracle, Pure Storage, and more. Explore Lydall's tech stack below.

Microsoft SharePoint
Content Management System
Oracle
Enterprise
Pure Storage
Enterprise Data Storage
Covisint
IT Infrastructure
Red Hat
Operating Systems
Microsoft Azure
Platform As A Service
VMware
Virtualisation Software
iCheck
Web Tools And Plugins

Media & News

NewAmsterdam Pharma: Cholesterol-Lowering Player Is A Risk-On Buy Today
NewAmsterdam Pharma is advancing obicetrapib, an oral CETP inhibitor, targeting unmet LDL-C lowering needs in cardiovascular disease patients. Obicetrapib met primary and secondary endpoints in three Phase 3 trials, with significant LDL-C reductions and favorable safety, supporting regulatory filings in Europe and the US. NAMS anticipates regulatory decisions in Europe in H2 2026, with US NDA likely post-PREVAIL CVOT data; commercial preparations and partnerships are underway.
Apr 16, 2026 | seekingalpha.com
Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins
RAHWAY, N.J.--(BUSINESS WIRE)--Enlicitide, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions Compared to Oral Non-Statin Therapies.
Mar 30, 2026 | www.businesswire.com
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company's partner in Canada for the development and commercialization of NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe), has received approval from Health Canada to market NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease. Commercial launch for NILEMDO is expected in Q2 2026.
Nov 18, 2025 | www.globenewswire.com
Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial
RAHWAY, N.J.--(BUSINESS WIRE)--Merck's Enlicitide, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with HeFH in Phase 3 CORALreef HeFH Trial.
Nov 09, 2025 | www.businesswire.com
Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
RAHWAY, N.J.--(BUSINESS WIRE)--Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial.
Nov 08, 2025 | www.businesswire.com
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse models Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse models
Oct 09, 2025 | www.globenewswire.com
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C
MUNICH, Germany--(BUSINESS WIRE)--Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal.
Aug 30, 2025 | www.businesswire.com

Lydall's Email Address Formats

Lydall uses at least 1 format(s):

Lydall Email Formats	Example	Percentage
FLast@lydall.com	JDoe@lydall.com	92%
First.Last@lydall.com	John.Doe@lydall.com	6%
LFirst@lydall.com	DJohn@lydall.com	1%
LastF@lydall.com	DoeJ@lydall.com	1%

Frequently Asked Questions

Where is Lydall's headquarters located?

Lydall's main headquarters is located at 1 Colonial Road Manchester, Connecticut 06042 United States. The company has employees across 3 continents, including North AmericaEuropeAsia.

What is Lydall's phone number?

You can contact Lydall's main corporate office by phone at

+1-860-646-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Lydall's stock symbol?

Lydall is a publicly traded company; the company's stock symbol is LDL.

What is Lydall's official website and social media links?

Lydall's official website is lydall.com and has social profiles on LinkedIn.

What is Lydall's SIC code NAICS code?

Lydall's SIC code is 8711 - Engineering Services NAICS code is 3332 - Industrial Machinery Manufacturing.

How many employees does Lydall have currently?

As of April 2026, Lydall has approximately 539 employees across 3 continents, including North AmericaEuropeAsia. Key team members include Chief Information Officer: J. T.Chief Audit Executive: G. D.Vp Associate General Counsel And Chief Compliance Officer At Vontier: H. S.. Explore Lydall's employee directory with LeadIQ.

What industry does Lydall belong to?

Lydall operates in the Industrial Machinery Manufacturing industry.

What technology does Lydall use?

Lydall's tech stack includes Microsoft SharePointOraclePure StorageCovisintRed HatMicrosoft AzureVMwareiCheck.

What is Lydall's email format?

Lydall's email format typically follows the pattern of FLast@lydall.com. Find more Lydall email formats with LeadIQ.

Insights

Similar companies to Lydall

Ingersoll Rand

Aearo Technologies

Lydall Tech Stack

Media & News

NewAmsterdam Pharma: Cholesterol-Lowering Player Is A Risk-On Buy Today

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C

Lydall's Email Address Formats

Frequently Asked Questions

Where is Lydall's headquarters located?

What is Lydall's phone number?

What is Lydall's stock symbol?

What is Lydall's official website and social media links?

What is Lydall's SIC code NAICS code?

How many employees does Lydall have currently?

What industry does Lydall belong to?

What technology does Lydall use?

What is Lydall's email format?

Lydall

Company Overview

Media & News

NewAmsterdam Pharma: Cholesterol-Lowering Player Is A Risk-On Buy Today

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?